Is Johnson & Johnson A Better Bet Compared To Bristol-Myers Squibb After 15% Decline?

Based on historical performance, Johnson & Johnson (NYSE: JNJ) appears to be less attractive compared to Bristol-Myers Squibb in the current crisis. The current coronavirus crisis will likely impact pharmaceutical companies on two fronts, 1. supply chain disruptions, and 2. potential impact on...